Investigation Of Pharmaceutical Service In Adjuvant Endocrine Therapy Of Breast Cancer

Objective:To probe into the status quo and its indency of adjuvant endocrine therapeutic drugs for breast cancer patients in our hospital by clinical pharmacists. And to include all these factors which could influence the standardization of adjuvant endocrine therapy, in order to provide appropriate pharmaceutical service for the special portion. Furthermore,to demonstrate the significance of clinical pharmacists’ direct participation in the work and to furnish corroborating evidence for establishing the work way of clinical pharmacists.Methods:(1)We reviewed the kinds, quantities and the consumption sum of the endocrine therapeutic drugs of breast cancer for inpatients in our hospital from2007to2010and analyzed the defined daily doses (DDDs) and daily drug cost (DDC) and other indicators of those drugs.(2) A total of162women with breast cancer after operation were treated with endocrine therapy for the first time from2010to2011, and the reasonable of their therapy were evaluated.(3)Retrospectively selected44patients received endocrine therapy from January2010to December2010(clinical pharmacists provided no pharmaceutical care) for the control group, and48patients received endocrine therapy from January2011to December2011(clinical pharmacists provided pharmaceutical services) for the observation group. During the treatment, adverse drug reactions (ADR) and drug interactions, compliance, the awareness of patients on drug knowledge and clinical pharmacists’ work were followed up.Results:(1)The average growth rate of total consumption sum of endocrine therapeutic drugs for breast cancer patients had been more than60%during the period2007-2010. Among the total, third-generation aromatase inhibitors (AIs) growthed rapid. DDDs high to low sorted by tamoxifen, letrozole, exemestane, anastrozole, toremifene; DDC high to low sorted by anastrozole, letrozole, exemestane, toremifene, tamoxifen.(2)28from162patients’ initial endocrine treatment (17.28%) did not match with the evaluation criteria, belong to the irrational use of drugs.(3)The difference between two groups in the re-examination rate of ADRs related indicators and clinical pharmacists indicators was statistically significant (P<0.05).Conclusions:The total use of endocrine therapeutic drugs of breast cancer was increased greatly, which was consistent with the guidelines recommend. Endocrine therapy as one of the comprehensive treatments of breast cancer had hold more clinical attention, but the drug selection and the use of opportunity still exists something unreasonable. Clinical pharmacists play an important role in breast cancer adjuvant endocrine therapy who can effectively improve the medication adherence of patients and promote rational use of medicines.